Qi Miao

5PUBLICATIONS
35CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Instrumental methods (excl. immunological and bioassay methods)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jan 08, 2024
Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy.

Sunita Keshari, Alexander S Shavkunov, Qi Miao

|Jul 26, 2023
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering.

Li Li, Vakul Mohanty, Jinzhuang Dou

|Feb 19, 2022
BHLHE40 Regulates the T-Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy.

Avery J Salmon, Alexander S Shavkunov, Qi Miao

|May 14, 2021
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies.

Lucila N Kerbauy, Nancy D Marin, Mecit Kaplan

|Dec 20, 2020
Ab initio spillover compensation in mass cytometry data.

Qi Miao, Fang Wang, Jinzhuang Dou

Pageof 1

Frequent Collaborators

5 joint publications

Ken Chen

2 joint publications

Mecit Kaplan

2 joint publications

Matthew M Gubin

2 joint publications

Sunita Keshari